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Abstract
Background Mental health care has lagged behind other health-care
domains in developing and applying shared decision making (SDM)
for treatment decisions. This is despite compatibilities with ideals of
modern mental health care such as self-management and recovery-
oriented practice, and growing policy-level interest. Psychiatric med-
ication is a mainstay of mental health treatment, but there are
known problems with prescribing practices, and service users report
feeling uninvolved in medication decisions and concerned about
adverse eﬀects. SDM has potential to produce better tailoring of
psychiatric medication to individuals’ needs.
Objectives This conceptual review argues that several aspects of
mental health care that diﬀer from other health-care contexts (e.g.
forms of coercion, questions about service users’ insight and disem-
powerment) may impact on processes and possibilities for SDM. It
is therefore problematic to uncritically import models of SDM devel-
oped in other health-care contexts. We argue that decision making
for psychiatric medication is better understood in a broader way that
moves beyond the micro-social focus of a medical consultation. Con-
textualizing speciﬁc medication-related consultations within longer
term relationships, and broader service systems enables recognition
of the multiple processes, actors and agendas that shape how psychi-
atric medication is prescribed, managed and used, and which may
facilitate or impede SDM.
Conclusion A broad conceptualization of decision making for psy-
chiatric medication that moves beyond the micro-social can account
for why SDM in this domain remains a rarity. It has both conceptual
and practical utility for evaluating research evidence, identifying
future research priorities and highlighting fruitful ways of develop-
ing and implementing SDM in mental health care.
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Introduction
Shared decision making (SDM) about treatment
options is now a widely recognized aspect of
patient-centred care that has become a modern
health-care ideal internationally.1 In SDM
patient and clinician discuss treatment options in
a two-way exchange of information and knowl-
edge (formal and experiential), and together
decide on a course of action.2 This collaborative
process is based on mutual respect, open commu-
nication and consideration of individual
preferences and values. In the UK, SDM is pro-
moted in government policies,3 good practice
guidance4 and initiatives to shape standard
clinical practice.5 A large body of research has
shown positive eﬀects on patient satisfaction,
treatment adherence, health status and health
inequalities.6–8
In the ﬁeld of mental health,a SDM has
received much less attention7–9 and remains a
relative rarity in standard clinical practice.10 A
systematic review of SDM interventions in men-
tal health found only two eligible studies and
concluded that further research was urgently
needed.11 However, there is growing interest in
SDM in mental health, which has increasingly
featured in mental health policy and good prac-
tice rhetoric,12,13 and ﬁts well with the ‘recovery’
approach that characterizes modern mental
health-care ideals in many developed coun-
tries.14–17 This patient-centred orientation
promotes self-management and aims to support
people to live well with and beyond their mental
health problems, combining formal treatments
with other well-being strategies.18 Experiential
knowledge is valued, and more equal, collab-
orative practitioner–user relationships are
promoted.
Despite these recent developments, shadows
of a darker past still characterize many aspects
of standard mental health practice. Forms of
coercion from subtle persuasion to compulsory
hospitalization or community treatment orders
(CTOs) are still relatively common. Many men-
tal health service usersb remain disempowered,
feel they have little voice in treatment decisions,
or that these are not made in their interests, and
experience stigma.19 Whilst there may be
moments of genuine lack of capacity, meaning-
ful dialogue can also sometimes be compromised
by practitioners’ assumptions about lack of
insight associated with mental health problems.
This may exaggerate inequalities between service
users’ experiential knowledge and the scientiﬁc
knowledge base of practitioners. These dynamics
are most common when mental health problems
are acute or severe (although they may not be
explicitly acknowledged by service providers),
but discrete experiences of threatened, perceived
or actual coercion can erode service users’ long-
term ability to trust and engage positively
with services.
Our focus in this paper is speciﬁcally on SDM
for psychiatric medication management within
specialist mental health services. Psychiatric
medication (antipsychotics, mood stabilizers,
antidepressants and anxiolytics) is a mainstay of
treatment for mental health problems, particu-
larly for psychotic disorders and acute mental
health crises. Again, there is a disjuncture
between policy ideals and much of standard clin-
ical practice. Whilst the value of patient choice
and active involvement in medication decisions
is emphasized in practice recommendations and
policies,13,20–23 mental health service users com-
monly report feeling uninvolved in decisions
about medication and often feel they lack
choice.10,13,24,25 Medication can be bound up
with forms of coercion: Service providers may
persuade or pressure users to take medication,
or to have long-acting ‘depot’ injections if they
do not take oral medication as practitioners
would like. Taking medication as prescribed can
be a requirement of legally binding CTOs, or a
determining factor of voluntary or compulsory
hospital admission status.
aWe focus in this paper on specialist mental health services,
whilst acknowledging that many common mental health
problems such as depression and anxiety are managed exclu-
sively in primary care. Some, but not all, of our arguments
may apply to primary care settings.
bWe prefer ‘service user’ over ‘patient’ as this is the most
commonly used term in mental health, and confers a more
active role on the person.
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Medications such as antipsychotics, mood sta-
bilizers and antidepressants are powerful drugs
that are usually taken for long periods of time
(often decades) and can produce a wide range of
wanted and unwanted physical and psychologi-
cal eﬀects. Prescribing the most appropriate type
and dose of medication is a complex process of
negotiating uncertainties in diagnosis, individual
responses and patient acceptability. These
challenges make the combination of users’ expe-
riential knowledge and practitioners’ clinical
knowledge within SDM a valuable approach in
achieving optimal medication use for an individ-
ual. Simultaneously, the potential for psychiatric
medication to be linked with coercion imposes
diﬀerent meanings and implications on these
discussion compared to other forms of medicine-
taking.
In this paper, we suggest that several character-
istics of mental health care (and the use of
psychiatric medication within this) mean it is
problematic to uncritically apply conceptualiza-
tions of SDM developed in other domains of
health care to mental health contexts. This is
because features such as disempowerment, forms
of coercion, questions about service users’ ‘in-
sight’ and stigma, that are more prominent than
in other health-care contexts, impact on the pro-
cesses and possibilities of SDM. The majority of
SDM work has had a primarily micro-social
focus on doctor–patient consultations.6,26–28 We
propose a conceptualization of decision making
for psychiatric medication that moves beyond the
micro-social, and contextualizes doctor–patient
interactions within longer term relationship and
treatment processes, and broader organizational
contexts in which many of the unique aspects of
mental health care are lived out. This area is in its
infancy, and the research base is small11 with con-
siderable methodologically and disciplinary
diversity, and little consensus on objectives, tar-
get groups or outcomes. Therefore, a conceptual
review that promotes critical thinking and con-
ceptual clariﬁcation is timely, and arguably has
more utility at this stage than a conceptually
uncritical systematic review.
After a brief review of the prescription and
management of psychiatric medication the
components of our broader conceptualization
are set out. We use this to integrate and criti-
cally evaluate existing evidence on SDM for
psychiatric medication and to identify direc-
tions for future research and clinical practice.
Psychiatric medication: prescription and
use
Experiences of taking psychiatric medication
Although many service users report beneﬁts of
psychiatric medication, concerns about the
impact of adverse eﬀectsc on life quality, well-
being and social functioning are common.29,30
Common negative eﬀects include weight gain,
drowsiness and mental clouding, reduced libido,
involuntary movements and diabetes. Users can
often ﬁnd themselves swapping symptoms of
mental ill health for another set of problems.24
Consequently, not taking medication as pre-
scribed is widespread: between a third and a half
of people do not take prescribed psychiatric
medication at all, take less than the prescribed
dose or stop taking it abruptly.31 These prac-
tices, especially abrupt stopping of medication,
can be associated with deteriorations in mental
health and increased likelihood of relapse.32
Psychiatrists are therefore justiﬁably wary of
users not taking medication as prescribed, but
they often fail to recognize this as part of posi-
tive self-management strategies. Over time,
many people learn to successfully tailor their
medication in response to mental states and life
events, integrating this into broader recovery
and ‘personal medicine’ strategies.33,34 ‘Purpose-
ful non-adherence’ is a common strategy to
minimize medication intake that is seldom dis-
closed to prescribers.35,36 Psychiatric medication
carries complex and ambivalent meanings linked
to identity and sense of self.37 Not taking medi-
cation may be an attempt to regain control in
response to negative or coercive experiences of
mental health care: it can be a service user’s
cWe prefer the terms ‘adverse’ or ‘negative’ eﬀects over the
more commonly used ‘side eﬀects’, as this risks diminishing
their signiﬁcance and centrality in users’ lives.
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‘trump card’, their only and ultimate source of
resistance in a context of experienced powerless-
ness and lack of choice.
Prescribing practices
Several concerns have been raised recently about
high dose and overprescribing of psychiatric
medication, and failure to follow prescribing
guidelines. A signiﬁcant proportion of UK users
of antipsychotics are prescribed more than
100% of the recommended maximum dose.10,20
Doses are often increased during a mental health
crisis, but not reduced once the crisis is resolved.
Polypharmacy is common,10 bringing greater
adverse eﬀects risks associated with drug interac-
tions or higher overall doses.38
Doubts about the balance of eﬃcacy vs.
adverse eﬀects have been expressed, with argu-
ments that the eﬃcacy of antipsychotics and
other medications may have been overestimated,
and the seriousness of adverse eﬀects underesti-
mated.39 Adverse eﬀects are likely to be more
severe on high doses, and some can be irre-
versible and associated with serious long-term
negative health consequences.40,41 The dominant
disease-targeting model of psychiatric medica-
tion has been questioned, giving greater weight
to users’ subjective experiences as the target of
treatment, not just an interesting by-product42.
Research shows that many people can live
well with no or low doses of medication, often
by developing positive strategies for managing
symptoms or within strong supportive
networks.43,44 Within the UK public mental
health system, there is little development of
such approaches.
Prescriber–user discussions about medication
Medication is one of the most important deci-
sional domains for mental health service
users,45 but they report receiving little or insuf-
ﬁcient information about adverse eﬀects,10,29
diﬃculties in raising medication concerns with
psychiatrists and low levels of involvement in
medication decisions.10,13,25,36 Micro-analytic
studies of psychiatric consultations support
this. In several domains including medication,
psychiatrists rarely use communication strate-
gies that encourage SDM (although wide
variations are found) and often use strategies
to resist engagement with users’ concerns and
questions.46,47 When discussing antipsychotics,
they frequently fail to address users’ concerns
about sedation and mental clouding, some-
times by questioning the validity of patients’
interpretations.48 The ‘option set’ (the choices
from which to decide) is often unilaterally
deﬁned by psychiatrists who may steer users
towards a particular decision or mark one
course of action as best.49 These studies sug-
gest that psychiatric consultations often fail to
support patient choice and SDM for psychi-
atric medication and can be unequal in terms
of participants’ access to information and
means of persuasion. To understand this, we
need to consider the multilevel factors that
contribute to these processes.
A conceptual model of decision making for
psychiatric medication
Our conceptualization of decision making for
psychiatric medication builds on and extends
the arguments of other commentators for
broader SDM models that move beyond the
micro-social, and includes factors such as pro-
fessional ethics, accountability and treatment
option constraints.26,27,50 It provides a struc-
tural representation of the domains within
which features of mental health care that are
unique, or more exaggerated than in other
health-care domains, operate (e.g. forms of
coercion, questions about ‘insight’, user disem-
powerment) and impact on decision-making
processes and possibilities for SDM (Fig. 1).
The micro-social processes of a psychiatric
consultation are embedded within a longer
term relationship, and a service context that
includes other key players (professional and
non-professional), and functional and cultural
features of the mental health-care system. This
is dynamic over time (so the three-dimensional
components in Fig. 1), in recognition that
mental ill health and its management may
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evolve through periods of wellness and relapse,
and SDM within this is a long-term process.
We propose this conceptualization as a
heuristic framework that informs our research
on SDM for psychiatric medication51,52 and
may enable other researchers to clarify and
critically consider relevant interactive, rela-
tional and systemic processes identiﬁed by
work in shared decision making, mental health
and medical sociology. It should not, however,
be considered as a tool to guide speciﬁc clinical
encounters. With modiﬁcations, it may also
help researchers to conceptualize other treat-
ment decisions in mental health or decision
making for psychiatric medication managed in
primary care settings. In the following sections,
we discuss the inter-related components of
this model.
The psychiatric consultation
At the micro-social level, we highlight two char-
acteristics of medication discussions between
practitioners and service users that may diﬀer
from standard models of SDM developed in
other areas of health care. First, the status and
value of mental health service users’ experiential
knowledge is ambivalent. On the one hand, users
are increasingly recognized as ‘experts by experi-
ence’ within recovery-oriented practice, and
their accounts of subjective experiences are
acknowledged as essential to judging the impact
of medication. One the other hand, if judged to
lack capacity or insight, the validity of their
views and subjective experiences can be ques-
tioned or devalued. This may lead to treatment
preferences being discounted, over-ruled or, at
Longer-term 
therapeutic relationship
Mental Health 
System
Structural, functional and cultural features
Psychiatric 
consultation
Figure 1 Decision making for psychiatric medication. *e.g. community psychiatric nurse, social worker, pharmacist,
psychologist, peer support worker.
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its extreme, choice being removed. This seldom
happens in other domains of health care, in
which patients’ views are generally considered
valid even if they disagree with practitioners.
Second, standard SDM models, in which
building and reaching consensus about treat-
ment are deﬁning characteristics,2 fail to capture
the complex and conﬂictual processes that char-
acterize some psychiatric consultations. When
practitioner and service user fundamentally dis-
agree about whether the person is mentally ill or
medication is desirable, a shared decision accept-
able to both parties may not be achievable.
Treatment decisions that are weighted towards
risk or safety concerns, and based on more than
simply the interests of the individual, may place
limitations on SDM, although services may be
reluctant to acknowledge this explicitly. For
example, choices between types of medication
may be retained, but decisions to not take medi-
cation, or to receive medication in tablet rather
than depot form may be removed from the
option set oﬀered by practitioners. Attempting
to maintain partnerships despite disagreements,
and encouraging respectful and open discussions
can allow these more challenging situations to
conform to processes of SDM that may confer
beneﬁts,53 even if a shared decision as an out-
come is not possible, such as when compulsory
treatment is enforced. Thus, the possibilities for
SDM within a single psychiatric consultation
relate to agendas in the broader organizational
and social context of mental health care.
Decision making within therapeutic relationships
Strong therapeutic relationships between mental
health service users and practitioners are central
to users’ experiences and treatment outcomes.54
Similarly, SDM processes rely on good thera-
peutic relationships between practitioner and
service user,16,55 allowing discussions to broaden
from simple ‘technical’ discussions of pros and
cons, to co-constructing understandings of medi-
cation in relation to a person’s life circumstances
and goals.27 In turn, this may contribute to fur-
ther enhancing partnerships and collaborations
over the longer term. Within a recovery-oriented
framework, giving greater weight to service
users’ experiential knowledge shifts the practi-
tioner’s role from authority to coach oﬀering
specialist knowledge,15 such that decisions about
medication become ‘an open experiment
between two co-investigators’.16,p. 1626 As peo-
ple’s understanding of their mental ill health and
its management develops over time, they may
become increasingly empowered to participate
as equal partners in discussions and choices
about medication. Thus, SDM has the potential
to be not just a means of deciding on treatment,
but an important part of treatment itself,
promoting agency and self-management, and
potentially contributing to raising trust and
improving therapeutic relationships. Progressive
development of SDM within positive therapeutic
relationships may protect against experiences of
disempowerment or alienation from services in
crisis situations, or when a person’s ability to
participate in decisions is compromised.
Conversely, the association between therapeu-
tic relationships and medication management
practices can sometimes have mutually reinforc-
ing negative impacts. Detrimental eﬀects on
therapeutic relationships have been found fol-
lowing 2 years of taking medication by long-
acting injection,55 and poor relationships with a
prescriber and experiences of coercion during
admission predict negative attitudes to antipsy-
chotic treatment.56 Such negative experiences
erode trust and may undermine future possibili-
ties for SDM. Our research shows that fear of
coercion is a barrier to mental health service
users’ involvement in medication decisions, and
prevents disclosure of symptoms or personal
adaptations to medication use.51
Involvement of multiple stakeholders
Whilst the psychiatric consultation may be
where ﬁnal decisions about medication are
made, much of the emotional, informational and
evaluative work behind treatment preferences
occurs outside this context, and is typically ‘dis-
tributed’ within social networks.53,57 Family
members can often collaborate positively in
these processes, although their role has been
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under-acknowledged in both SDM research and
mental health care. As well as local support net-
works, internet forums are increasingly sources
of emotional support, knowledge gain and conﬁ-
dence-building.
The role of other health practitioners has also
been under-acknowledged in SDM models.58
Psychiatric nurses, social workers, psychologists
and peer support workers may meet mental
health service users more regularly than
prescribing psychiatrists, providing opportunities
to discuss medication.59,60 Non-medical practi-
tioners can make various contributions to
medication decisions, including exploring con-
cerns, preferences, aspirations and perceived
beneﬁts and problems of medication; providing
support to seek out or understand medication
information; helping service users prepare for
psychiatric consultations by clarifying what they
want to discuss; or accompanying them to con-
sultations. In these ways, they may amplify the
voice of service users who lack conﬁdence to
express their views honestly with psychiatrists.
Our work suggests psychiatric nurses and care
co-ordinators see themselves as ‘walking a shared
journey’ with service users, are positive about
SDM and may recognize the value of service
users’ experiential knowledge more than psychia-
trists,51 but often feel under-conﬁdent about
having suﬃcient or appropriate medication
knowledge to discuss choices in depth.52 Primary
care physicians or general practitioners (G.Ps)
may also be involved in monitoring or prescrib-
ing medication, and, for the antidepressants and
anxiolytics, are often solely responsible for these
tasks. However, they may be less knowledgeable
about psychiatric medication than their psychi-
atric colleagues, and reluctant to reduce or
change doses recommended by psychiatrists.
The roles of various practitioners and sup-
porters may vary across a person’s illness
trajectory as they move between diﬀerent part of
the health system (for example, between primary
and specialist services, or between inpatient and
community-based care). Across service settings,
users may encounter diﬀerent opinions about
medication and involvement in decision making,
shaping their expectations for each new clinical
encounter. Medication-related decision making
typically involves numerous knowledge-based,
values-based and interactive processes dis-
tributed over a network of stakeholders and
supporters across contexts and time, with the
service user as the constant factor.
The mental health system as the context for SDM
We have already discussed features of contem-
porary mental health-care systems that may
facilitate SDM (policy rhetoric in support of
patient choice, and recovery-oriented approaches),
and those unique to mental health care that pre-
sent challenges to SDM (forms of coercion,
questions about insight and capacity). Processes
and possibilities of SDM speciﬁcally for psychi-
atric medication may be shaped by other
systemic factors including: a short-term and risk-
averse service culture that prioritizes relapse
avoidance over the potential harm of long-term
medication use; reliance on biomedical models of
mental illness that prioritize medication and
medical expertise over other treatment strategies;
dominance of a disease-targeting model of psy-
chiatric medication that may obscure alternative
explanations42; professional pessimism about
long-term prognosis; lack of prescriber conﬁ-
dence about reducing or stopping medication61;
the relationships of psychiatry with the pharma-
ceutical industry; psychiatry’s broader societal
role in regulating behaviour, and the use of medi-
cation in this; and (particularly in the current
UK context) resource limitations that reduce
regular contact with psychiatrists.
Locating existing evidence within this
conceptualization
This conceptualization of decision making for
psychiatric medication can be used to evaluate,
position and integrate relevant research from a
range of disciplinary areas.
Stakeholders’ preferences and concerns
In keeping with the micro-social focus of much
SDM research,26 a considerable amount of
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research has explored practitioners’ and service
users’ preferences and concerns regarding medi-
cation-related decision making. These are key
facilitators or barriers to implementing SDM.
Many mental health service users want more
involvement in treatment decisions, and medica-
tion decisions in particular.24,25,62 Whilst there
are individual diﬀerences in relationships with
medication35 and decision making preferences,63
involvement preferences are not static traits, but
related to experience and stages of illness.64,65
Service users often prefer a more directive practi-
tioner style in times of crisis.51 They may
become more conﬁdent users of both medi-
cation and services over time,37 especially if
supported to develop greater autonomy and self-
management skills.15 This supports our dynamic
conceptualization and suggests that SDM is not
a ‘one size ﬁts all’ process but should be tailored
to the preferences, needs and illness stage
of individuals.
For their part, psychiatrists express ‘cautious
willingness’ about SDM,9,p. 4 and some report
already practicing aspects of SDM.61,66 Practi-
tioners’ reservations are most commonly about
service users’ competence to participate in deci-
sion making at some stages of their illness,61,67
and that SDM will require more time.58,60,68
Some psychiatrists think medication decisions
are less suitable for SDM than other care deci-
sions,66 and fear that discussing adverse eﬀects
could discourage medication use.61 Little is
known about the views of non-medical mental
health practitioners,68 or about family car-
ers’ views.
Interventions to enhance SDM
Compared to the wealth of SDM work in other
health domains,6 only a small number of studies
exist in mental health.11 Those focusing on
or including medication decisions have pro-
duced some positive results using interventions
targeted at various practitioners (not just pre-
scribing psychiatrists). A randomized trial of
SDM training for nurses and psychiatrists in
inpatient settings showed that nursing support
to use a decision aid in advance of psychiatric
consultations increased acutely unwell service
users’ knowledge and decisional involvement.69
However, involvement was not sustained over
time, a fact attributed by the authors to the one-
oﬀ nature of the intervention. Other studies have
recognized the value of interventions targeting
longer term processes. For example, structuring
meetings around users’ needs and concerns in
several domains including medication over a 12-
month period produced positive eﬀects on sub-
jective life quality, unmet needs and treatment
satisfaction.70 Training care co-ordinators in
eﬀective medication management using SDM
principles led to improvements in clinical symp-
toms and service user involvement, and
reductions in antipsychotic doses, depots and
polypharmacy after 9 months.71 However, a sole
focus on practitioner training and reliance on
practitioners to encourage user participation risk
the impact on service users being potentially
diluted by poor practitioner implementation and
omit the training needs of service users to enable
conﬁdent and active decisional involvement.
A promising intervention that targets service
users directly is ‘Common Ground’.72 Devel-
oped in the USA, this provides computerized
recovery-oriented information and medication-
related decision aids. A report on the person’s
concerns, preferences and goals is reviewed in
a psychiatric consultation and used to guide
subsequent courses of action. Increased involve-
ment in medication decisions and disclosure of
information and concerns that users found diﬃ-
cult to tell psychiatrists directly were found.72
When implemented in 12 outpatient clinics, the
programme was used by 85% of service users
and was associated with increases in self-
reported overall health and perceived helpful-
ness of psychiatric medication, and reductions in
symptoms and concerns about negative medica-
tion eﬀects.73 This suggests a valuable role in
improving the tailoring of medication to individ-
uals’ needs.
Our conceptualization of decision making
for psychiatric medication suggests that inter-
ventions directly targeting both sides of
practitioner-service user dyads (or indeed all
stakeholders in decisional processes) have the
ª 2015 The Authors Health Expectations Published by John Wiley & Sons Ltd.
Health Expectations, 19, pp.1002–1014
Psychiatric medication management, N Morant, E Kaminskiy and S Ramon 1009
greatest potential to impact on established roles
and interactive processes in a psychiatric consul-
tation. Our current ‘ShiMME’ project is unique
in providing SDM training simultaneously to
service users, psychiatrists and multidisciplinary
care co-ordinators.52 Both ‘ShiMME’ and
‘Common Ground’ avoid the pitfalls of an
exclusively micro-social focus by taking account
of facilitators and barriers to SDM within the
mental health system. Whilst inequalities
of knowledge and power can be barriers to
involvement in general health care,74 our con-
ceptualization highlights how greater levels of
disempowerment, stigma and coercion in mental
health settings may exaggerate barriers to
involvement. Therefore, peer support and conﬁ-
dence-building are central to ‘ShiMME’ training
which is provided in group format by user-
trainers.52 Institutional inequalities are also
addressed by including user perspectives in prac-
titioner training. In ‘Common Ground’ peer
workers provide support in using the computer
package and exploring and articulating con-
cerns. Both projects capitalize on facilitative
factors within the organizational culture, by
integrating SDM with other well-being, recovery
and self-management strategies. ‘Common
Ground’ also engages with structural limitations
of the organizational context by reconﬁguring
outpatient clinics to include a ‘Decision Support
Centre’ and scheduling time in advance of psy-
chiatric appointments for service users to work
with peers within this. This enables consultation
times to remain the same whilst focussing them
more eﬃciently on service users’ concerns.
Implications for research and clinical
practice
More research is needed on interventions to pro-
mote SDM for psychiatric medication, and on
implementation and sustainability issues. Speci-
ﬁc gaps in our knowledge include the potential
contributions of non-prescribing mental health
practitioners, G.Ps, peer workers and family car-
ers, and the feasibility and limitations of SDM
in acute care settings and at times of mental
health crisis when coercion is most likely.
Based on our broad conceptualization, SDM
interventions that target all involved parties
(not just one member of practitioner–service
user dyads) and decision making over time
(rather than single or one-oﬀ decisions), and
acknowledge structural, cultural and functional
facilitators and barriers in the mental health sys-
tem are most likely to produce positive eﬀects.
For example, simply providing trustworthy and
understandable medication information or deci-
sion aids may be insuﬃcient to enable active and
equal service user participation in decisions,
unless accompanied by strategies to counter
existing asymmetries with practitioners.74 Conﬁ-
dence-building and empowerment should be
core components of SDM initiatives for service
users. SDM initiatives also need to be com-
patible with current mental health service
conﬁgurations. For example, in the UK context,
typically infrequent contact with a psychiatrist
may oﬀer limited scope for all aspects of SDM,
but opportunities exist for other practitioners to
implement components of SDM, such as explor-
ing values and goals or accessing user-
friendly information.
The training needs of these practitioners in
medication knowledge and SDM-related skills
need to be recognized and addressed. This
should include learning more about service
users’ experiences of medication, the positive
strategies they use to tailor medication intake to
individual needs and life circumstances, their
use of other well-being strategies and their social
support and informational resources. Training
should explicitly address how the standard
‘script’ of practitioner–service user meetings is
challenged by SDM, and the dilemmas raised by
marrying up SDM with professional account-
ability and risk considerations in complex or
conﬂictual clinical situations.22,40 Although
many practitioners believe they already practice
elements of SDM,58 discrepancies with service
users’ ratings of involvement suggest they may
be unaware of institutional or individual failures
to support involvement. Existing provider–user
inequalities in mental health, and ways of valu-
ing both scientiﬁc and experiential forms of
knowledge should be considered. Given that
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practitioners and users often disagree about the
role and value of psychiatric medication, train-
ing should consider how interactive processes
that are part of SDM (e.g. exploring values,
valuing experience) can be maintained when
agreement cannot be reached, or when interests
other than the service user’s shape treatment
decisions. This is important because the stron-
gest desire for more involvement has been
found among those with negative views of
psychiatric medication and treatment,62 who
potentially have much to gain from new forms
of dialogue or engagement with service provi-
ders. Finally, professionals should learn to
encourage and oﬀer SDM as much as possible,
whilst being sensitive to individual preferences
and their variations related to current
illness status.75
Collectively, service providers should con-
sider: how decision aids and other SDM tools
(e.g. medication diaries, comparative medica-
tion information) can be best integrated into
clinical practice; resources to help service users
prepare for time-limited and infrequent con-
sultations with prescribers; and whether
service reconﬁgurations may be necessary to
support SDM. Acceptability of SDM initia-
tives and implementation in clinical practice
may be greater if practitioners’ preconceptions
about SDM are acknowledged. Resistance
may stem from fears of relapse if users stop
taking medication; the balance between
positive risk-taking and professional account-
ability; and ceding professional power.
Overstretched practitioners’ concerns about
SDM requiring additional time may be
allayed by evidence that this is not the
case,47,58,69,70 especially if accompanied by ser-
vice reconﬁgurations.72
Conclusions
SDM has the potential to alleviate problem-
atic aspects of current psychiatric medication
management. It oﬀers greater choice and consid-
eration of a broader range of treatment options
and may produce better tailoring of medication
to individuals’ needs, preferences, lifestyle and
stage of illness, with knock-on eﬀects on health
and social functioning. Medical support of
graded reductions or changes in medication may
be more successful and less likely to lead to
relapse than if users unilaterally decide to stop
taking medication. Fundamentally, people are
more likely to stick with a course of action they
are happy with, or feel they have been involved
in deciding upon.
Despite this, SDM for psychiatric medication
remains an exception rather than the norm in
clinical practice. Our conceptual model of deci-
sion making for psychiatric medication has
potential to explain this. We have shown that
providing a more sophisticated account of the
multilevel factors shaping medication decisions
than existing SDM models that have a de-
contextualized focus on micro-social processes
enables us to:
1. highlight features of the mental health system
and psychiatric medication management that
diﬀer from, or are more exaggerated than in
other health care domains (e.g. the potential
for coercion, the status of experiential knowl-
edge), and the impact of these on decision-
making processes;
2. incorporate both the current realities of psy-
chiatric medication management and more
collaborative forms of these processes;
3. highlight multilevel facilitators and barriers
to SDM, and changes in processes and prac-
tices at interactive, relational and systemic
levels needed to develop more shared forms
of medication management;
4. integrate a broad range of theoretical and
empirical work relevant to this topic from
mental health research, medicine and medical
sociology.
By adopting a broader conceptual framework,
we can view SDM for psychiatric medication as
entailing a number of related processes both
within, and also beyond the psychiatric consulta-
tion: service users being provided with, or
autonomously seeking out medication informa-
tion, or being supported to do so by individuals
and social networks within and beyond the men-
tal health system; acquiring conﬁdence to voice
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their medication experiences and preferences,
and potentially disagree with prescribers; and
collaborative co-investigations of medication
options between a service user and one or more
practitioners. Many of these process challenge
established provider–user roles and relationships
and may require organizational and cultural
shifts. Our model aims to facilitate conceptual
and practical developments, and may help to
narrow the current gap between theoretical and
policy ideals, and clinical realities in an impor-
tant area of mental health practice.
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